Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
Biospace,
SEATTLE--(BUSINESS WIRE)-- Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune…